Dechert advised Antios Therapeutics on the deal. Antios Therapeutics, Inc. (“Antios”) completed its $96 million Series B financing. Antios is a clinical-stage biopharmaceutical company focused on the...
Dechert advised Antios Therapeutics on the deal. Antios Therapeutics, Inc. (“Antios”) completed its $96 million Series B financing. Antios is a clinical-stage biopharmaceutical company focused on the...